Preclinical News and Research

RSS
Therapeutic candidate BLU-554 has significant anti-tumor activity in HCC models

Therapeutic candidate BLU-554 has significant anti-tumor activity in HCC models

Study identifies BLU-554 as potential treatment option for HCC patients

Study identifies BLU-554 as potential treatment option for HCC patients

Glide's solid dose formulation of teriparatide achieves successful results in pre-clinical study

Glide's solid dose formulation of teriparatide achieves successful results in pre-clinical study

Glide's solid dose formulation of teriparatide achieves successful results in pre-clinical study

Glide's solid dose formulation of teriparatide achieves successful results in pre-clinical study

Remogliflozin etabonate: A potential treatment option for management of NASH and NAFLD

Remogliflozin etabonate: A potential treatment option for management of NASH and NAFLD

Botanical formula improves effect of tamoxifen drug in ER+ human breast cancer

Botanical formula improves effect of tamoxifen drug in ER+ human breast cancer

Honokiol extract holds promise as adjunct treatment for bladder and kidney cancers

Honokiol extract holds promise as adjunct treatment for bladder and kidney cancers

James Shapiro's latest research could soon mark new standard for diabetes treatment

James Shapiro's latest research could soon mark new standard for diabetes treatment

Female liver cells become more susceptible to adverse effects of drugs, study finds

Female liver cells become more susceptible to adverse effects of drugs, study finds

Cantrixil drug granted FDA Orphan Drug Designation for treatment of ovarian cancer

Cantrixil drug granted FDA Orphan Drug Designation for treatment of ovarian cancer

GenVec, Laboratory of Malaria Immunology and Vaccinology sign research collaboration agreement

GenVec, Laboratory of Malaria Immunology and Vaccinology sign research collaboration agreement

Designing AR Inhibitors Team wins AACR Team Science Award for developing prostate cancer treatment

Designing AR Inhibitors Team wins AACR Team Science Award for developing prostate cancer treatment

Ibrutinib (IMBRUVICA) may be effective for pancreatic ductal adenocarcinoma

Ibrutinib (IMBRUVICA) may be effective for pancreatic ductal adenocarcinoma

Effimune obtains regulatory approval for Phase I clinical trial in humans of its new immunomodulator FR104

Effimune obtains regulatory approval for Phase I clinical trial in humans of its new immunomodulator FR104

Research: Stem cell injection may soon slow or reverse effects of age-related macular degeneration

Research: Stem cell injection may soon slow or reverse effects of age-related macular degeneration

Moirai Orthopaedics receives FDA approval for IDE application to initiate clinical study of PIR System

Moirai Orthopaedics receives FDA approval for IDE application to initiate clinical study of PIR System

Pivotal enters into sales, distribution agreement for BeneFishial family of products

Pivotal enters into sales, distribution agreement for BeneFishial family of products

Cardio3 BioSciences announces first patient enrollment in NKG2D CAR T-Cell Phase I clinical trial

Cardio3 BioSciences announces first patient enrollment in NKG2D CAR T-Cell Phase I clinical trial

Experts to make roadmap for future research, clinical trials for SCLC patients at IASLC workshop

Experts to make roadmap for future research, clinical trials for SCLC patients at IASLC workshop

MR Solutions offers range of MRI scanners that can be placed within Class 3 and 4 laboratories

MR Solutions offers range of MRI scanners that can be placed within Class 3 and 4 laboratories

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.